How to perform COVID-19 prevention and therapy?

PATENT:

2793967

INVENTION:

Single-domain llama’s antibody H5 and its derivative H5-FC, specifically binding the RBD domain of the S-protein of the SARS-COV-2 virus, having virus neutralizing activity

INNVENTOR(S):

Baranov Konstantin Olegovich, Belovezhets Tatiana Nikolaevna, Volkova Olga Yuryevna, Gorchakov Andrey Alexandrovich, Guselnikov Sergey Vladimirovich, Kulemzin Sergey Viktorovich, Mechetina Lyudmila Vasilyevna, Nayakshin Alexander Matveevich, Solodkov Pavel Pavlovich, Taranin Alexander Vladimirovich, Chikaev Anton Nikolaevich, Chikaev Nikolai Andreevich

PATENTEE:

State Institute of Molecular and Cell Biology of the Siberian Branch of the Russian Academy of Sciences (IMCB SB RAS)

PURPOSE:

For the prevention and treatment of COVID-19

INNOVATION:

At present, several vaccines have been developed for the prevention and treatment of COVID-19. However, there is also an alternative method for emergency care – the use of antibodies against SARS-CoV-2, a number of which have already been developed. For the most part, these are antibodies designed for diagnosis. Among the antibodies intended directly for the prevention and treatment of COVID-19, the majority are classical monoclonal antibodies. At the same time, they have a number of disadvantages: the difficulty and high cost of obtaining and treating them due to the need to inject several grams of such antibodies intravenously, as well as due to difficulties in their biotechnological production due to the large size of the protein, its complex structure. To overcome these disadvantages, the most promising is the use of single-domain camelids’ antibodies.

Russian scientists have developed a single-domain llama’s antibody, which, in comparison with classical antibodies, has advantages, namely: high thermal stability, the ability to recognize antigens inaccessible to classical antibodies, cheapness of production, small size of antibodies, which allows delivering single-domain antibodies directly into the respiratory tract in the form of an aerosol, the possibility to use it for antigens resistant to mutational escape of the virus.

Currently, there are no drugs based on single-domain llama’s antibodies and their derivatives for the diagnosis and treatment of COVID-19 approved for use. Thus, a single-domain llama’s antibody that specifically binds to the RBD domain of the SARS-CoV-2 virus S-protein, which has virus neutralizing activity, is a promising invention.

SCOPE OF
APPLICATION:

The invention belongs to the field of biotechnology and medicine.

For more details please refer to the published patent.